Published in Gastroenterology on April 01, 2003
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol (2012) 1.63
11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev (2013) 1.60
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol (2006) 1.30
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol (2008) 1.25
Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol (2009) 1.24
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol (2005) 1.16
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis (2009) 1.10
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res (2008) 1.00
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol (2012) 1.00
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Ulcerative colitis-associated colorectal cancer. World J Gastroenterol (2014) 0.97
Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol (2008) 0.96
Intestinal bile acid physiology and pathophysiology. World J Gastroenterol (2008) 0.95
Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am (2010) 0.94
Colorectal cancer in inflammatory bowel disease. Gut Liver (2008) 0.94
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Intest Res (2014) 0.93
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol (2008) 0.93
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res (2010) 0.91
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol (2006) 0.90
Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila) (2009) 0.89
Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis. Br J Cancer (2007) 0.89
Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol (2014) 0.88
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol (2014) 0.88
Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci (2007) 0.87
Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int (2013) 0.87
Primary sclerosing cholangitis. Orphanet J Rare Dis (2006) 0.87
Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. BMC Cancer (2006) 0.86
Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol (2012) 0.86
Muscarinic receptor signaling in colon cancer. Cancers (Basel) (2011) 0.86
Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci (2014) 0.86
Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.85
Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis (2012) 0.85
Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis. BMC Infect Dis (2014) 0.85
Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc (2012) 0.85
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol (2009) 0.83
Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol (2009) 0.82
Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. Cancer Prev Res (Phila) (2011) 0.82
Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol (2009) 0.82
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2014) 0.82
Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci (2013) 0.82
Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: a case control study. BMC Med Genet (2008) 0.81
Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis (2013) 0.81
Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role? World J Gastroenterol (2014) 0.81
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells. World J Surg Oncol (2012) 0.80
Strategies for colon cancer prevention. EPMA J (2010) 0.80
The medical management of primary sclerosing cholangitis. Medscape J Med (2008) 0.79
Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers (Basel) (2012) 0.78
Overlap syndromes: an emerging diagnostic and therapeutic challenge. Saudi J Gastroenterol (2014) 0.78
Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.78
Ursodeoxycholic acid influences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis. J Immunol Res (2014) 0.77
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. Orphanet J Rare Dis (2013) 0.77
Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα. J Lipid Res (2012) 0.77
Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. MedGenMed (2006) 0.77
Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol (2016) 0.77
U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways. PLoS One (2014) 0.77
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. World J Gastroenterol (2016) 0.77
Controversies in the management of primary sclerosing cholangitis. World J Hepatol (2016) 0.76
Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol (2014) 0.76
Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol (2013) 0.76
The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. Medicine (Baltimore) (2016) 0.76
Chemoprevention of colorectal cancer. Dig Dis (2014) 0.76
In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig Dis Sci (2011) 0.76
Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls. Orphanet J Rare Dis (2013) 0.76
Hepatobiliary quiz-6 (2013). J Clin Exp Hepatol (2013) 0.75
Inflammatory Bowel Disease Associated Colorectal Neoplasia. J Gastrointest Dig Syst (2012) 0.75
Ursodiol: good drug makes good. Gastroenterology (2003) 0.75
Recurrence of autoimmune liver diseases after liver transplantation. World J Hepatol (2015) 0.75
Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. Cancer Prev Res (Phila) (2016) 0.75
Primary Sclerosing Cholangitis: Current and Future Management Strategies. Curr Hepat Rep (2013) 0.75
UC for UC: ursodiol chemoprevention for ulcerative colitis. Inflamm Bowel Dis (2003) 0.75
Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol (2016) 0.75
Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice. J Carcinog (2010) 0.75
Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects. Auto Immun Highlights (2012) 0.75
Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol (2017) 0.75
Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila) (2016) 0.75
Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS One (2017) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl (2005) 4.46
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Survival differences following lung transplantation among US transplant centers. JAMA (2010) 2.57
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation (2007) 2.43
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol (2013) 2.39
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis (2014) 2.19
Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. Mayo Clin Proc (2012) 2.17
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis (2008) 2.12
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med (2010) 2.06
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology (2013) 2.04
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology (2011) 1.99
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Retained Capsule Endoscopy in a Large Tertiary Care Academic Practice and Radiologic Predictors of Retention. Inflamm Bowel Dis (2015) 1.97
MELD is superior to King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl (2007) 1.94
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol (2002) 1.89
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis (2007) 1.85
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med (2013) 1.71
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. Transplantation (2006) 1.69
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol (2004) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol (2010) 1.62
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol (2003) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Hospitalisations and surgery in Crohn's disease. Gut (2012) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J (2008) 1.56
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg (2010) 1.54
Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53
Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis (2011) 1.51
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol (2004) 1.51
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion (2006) 1.49
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl (2004) 1.47
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol (2002) 1.45
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43